Board of Directors

Path 2

Dante Pennacchia




Mr. Pennacchia is a sales and marketing expert with over 25 years experience and successful execution in industries ranging from Consumer Products to Medical Devices and Geographic Information Systems. He has been successful with large, small and start-up businesses. While at ITT C&C Cola, he helped launch game changing consumer beverage products in the U.S., such as Perrier and Capri Sun. As Vice President of Sales and Marketing for a medical device subsidiary of Bausch & Lomb, he helped to grow that business from $26M to $120M in 7 years. After being promoted to VP of Consumer Healthcare Group Sales in 1996 for Bausch & Lomb Consumer Healthcare North America, Dante grew market share to the highest ever achieved at that time.

In June of 2001, he was recruited to a start-up company known as Pictometry International, a company with $14,000 in delivered sales. During his tenure as VP of Sales and Marketing and later as CMO he helped Pictometry became one of Rochester’s most successful technology companies, growing sales to over $100 million in 9 years.

Dante is Founder and President of Maxualize™ LLC, a coaching and consulting group focused on assisting start-up companies who want to grow their business. Dante is a Cum Laude graduate of Northeastern University in Boston, where he obtained a BS in Marketing. He was selected to take part in executive marketing courses at Amos Tuck at Dartmouth, Leadership courses at the Center for Creative Leadership at the University of Maryland, and the Global Executive training program at Cornell University. He is a former Diversity Champion at Bausch & Lomb and a sought after speaker on the subject to companies such as the Walt Disney Company.

Bradford Berk, MD, PhD




Dr. Berk is currently Director of the Rochester Neurorestorative Institute. Dr. Berk is also Distinguished Professor of Medicine, Pathology, and Pharmacology & Physiology at the University of Rochester. He received his M.D. and Ph.D. degrees from the University of Rochester. He has served on the faculties of Harvard Medical School, Emory University, and the University of Washington. Dr. Berk was previously CEO of the University of Rochester Medical Center (2006-2015) as well as Chairman of Medicine (1999-2006) and Chief of the Cardiology Unit (1998-2003) at the University of Rochester. In addition, he was Director of the Aab Cardiovascular Research Institute. Dr. Berk is a fellow of the American Heart Association and the American College of Cardiology, and a member of the Association of American Physicians.

Efrain Rivera, DM, MBA, JD




Efrain Rivera is the Senior Vice President, Chief Financial Officer and Treasurer of Paychex, Inc. Mr. Rivera is a senior financial executive with more than 20 years of experience in finance, accounting and business leadership positions, most recently as Vice President of Finance and Administration for Houghton College since 2009.

Mr. Rivera previously served as Corporate Vice President and Chief Financial Officer for Bausch & Lomb from 2007 to 2009 and, prior to that, as Corporate Vice President and Treasurer from 2004 to 2007. During his twenty years with Bausch & Lomb, Mr. Rivera served in various leadership and financial management roles, including Corporate Vice President and President, Canada and Latin America Division; and Vice President Finance and Controller, Global Vision Care.

A native of Paterson, New Jersey, holds a Doctor of Management degree from Weatherhead School of Management at Case Western Reserve University in Cleveland, Ohio. Additionally, he earned his Master of Business Administration from the William E. Simon Graduate School of Business at the University of Rochester in Rochester, New York, and a Juris Doctor degree from New York University in New York City.

Spencer Z. Rosero, MD



Dr. Rosero serves as the Chief Medical Officer of Efferent Labs, Inc. working with the Scientific Advisors and directing discovery activity.

Dr. Rosero is Professor of Medicine at the University of Rochester School of Medicine and Dentistry. He currently serves as Director of the Clinical Research Center -the Clinical and Translational Sciences Institute (CTSI) and as Clinical Director of the Center for Medical Technology and Innovation at the University of Rochester. He is a practicing cardiologist who developed the CytoComm™ and PlexiSense technology through years of work with patients. As a specialist in heart rhythm disorders, Dr. Rosero treats patients using a wide range of therapeutic options including radiofrequency ablation of abnormal rhythms, implantation of electronic medical devices such as pacemakers, defibrilllators (ICD’s), and cardiac resynchronization therapy devices.

Dr. Rosero is an experienced clinical investigator and has actively participated in several, large multicenter trials studying the role of medical devices in treating patients with heart failure and life threatening arrhythmias. As the site principal investigator for the early evaluation of a novel implantable left atrial pressure monitoring system at the University of Rochester, Dr. Rosero’s team was the first in the nation to implant the St. Jude Heart Pod device. His research interests include living cell embedded biosensors, hereditary arrhythmias and futuristic medical device technologies that support personalization of medical care.

W.K. (Bill) Rader



Mr. Rader is a serial entrepreneur who sold his first company at age 18. To date he has launched five ventures and orchestrated multiple M&A’s. Mr. Rader founded Efferent Labs, Inc. in 2011 with a passion derived from his personal experience. He created Efferent Labs on the shoulders of a company he founded in 1998 and successfully exited in 2015, Raland Technologies (now Raland Compliance Partners). Mr. Rader grew Raland from a one-man startup to an Inc. 500|5000 company with a global footprint and four divisions. While leading Raland, he established strategic office locations across the United States and provided services to clients including Fortune 500 pharmaceutical, biotech and medical device companies throughout the United States, Europe and Asia. His efforts enabled Raland to become one of the most highly respected and sought after providers within the Life Science industry.

Mr. Rader started his career in the engineering sector of the U.S. Navy as a Nuclear Engineering Reactor Controls member of the Submarine Fleet. He holds a Bachelor of Science in Electrical Engineering, is a member of Harvard Business School, Business Innovations in Global Healthcare class of 2015, and a graduate of the University at Buffalo, School of Management. Mr. Rader is on the Board of Directors for NY MedTech, a NYBio Fellow, and a member of many industry organizations including ISPE, PDA, IEEE, and ISA.